Scalper1 News
The genetic-testing industry has come under the microscope again after Myriad Genetics’ breast-cancer gene test got a big reimbursement cut from the federal government, adding pressure to a field whose 2014 outlook is cloudy. On Dec. 27, the Center for Medicare & Medicaid Services (CMS) said that starting Jan. 1 it will pay $1,438.14 for Myriad ‘s (MYGN) test for the BRCA 1 and 2 genes, as well as another test for the BRCA 1 gene alone. Earlier it Scalper1 News
Scalper1 News